A phase II study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy showed that a novel monoclonal antibody, known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body.
A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.
